This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sanofi, Boehringer Ingelheim consumer-healthcare deal approved in Brazil

( September 6, 2016, 10:46 GMT | Official Statement) -- MLex Summary: French drugmaker Sanofi has obtained antitrust clearance in Brazil to buy Boehringer Ingelheim’s consumer-healthcare business. The transaction is part of an asset swap in which Boehringer will trade its consumer-drug business, valued at 6.7 billion euros ($7.5 billion), for Sanofi’s animal-health business Merial, valued at 11.4 billion euros. Sanofi shares are listed on the Euronext Paris and the New York Stock Exchange.Read the OJ statement below:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login